<DOC>
	<DOCNO>NCT01624142</DOCNO>
	<brief_summary>A study ass long term safety efficacy Evolocumab ( AMG145 ) Low Density Lipoprotein-Cholesterol ( LDL-C ) subject severe familial hypercholesterolemia .</brief_summary>
	<brief_title>Trial Assessing Long Term USe PCSK9 Inhibition Subjects With Genetic LDL Disorders</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participated qualify Evolocumab ( AMG145 ) parent protocol OR Have diagnosis familial hypercholesterolemia AND Males females ≥ 12 ≤ 80 year age Stable lowfat diet lipidlowering therapy least 4 week Low Density Lipoprotein Cholesterol ( LDLC ) &gt; =130 mg/dl ( 3.4 mmol/L ) subject without diagnose CHD/CHD risk equivalent OR LDLC &gt; = 100 mg/dl ( 2.6 mmol/L ) subject diagnose CHD CHD risk equivalent OR apheresis patient LDLC entry requirement Fasting triglycerides &lt; 400 mg/dL ( 4.5 mmol/L ) Bodyweight &gt; 40 kg great screen subject less 18 year age New York Heart Failure Association ( NYHA ) class III IV last known leave ventricular ejection fraction &lt; 30 % Myocardial infarction , unstable angina , percutaneous coronary intervention ( PCI ) , coronary artery bypass graft ( CABG ) stroke within 3 month screen Planned cardiac surgery revascularization Uncontrolled cardiac arrhythmia Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Elevated Cholesterol</keyword>
	<keyword>High Cholesterol</keyword>
	<keyword>Homozygous Familial Hypercholesterolemia</keyword>
	<keyword>PCSK9 mutation</keyword>
	<keyword>Severe Familial Hypercholesterolemia</keyword>
</DOC>